Search Results
Your search for The A,The A matches 33406 pages
Showing 22551 - 22600Supporting Cancer Research Through the Conquer Cancer Foundation
The Conquer Cancer Foundation of ASCO funds the brightest minds in clinical and translational cancer research through its Grants and Awards Program. Since its inception in 1984, the Grants and Awards program has awarded more than $100 million through more than 1,500 grants and awards to at least 65 ...
ASCO Unveils New Resources for MACRA Transformation
Are you ready for MACRA? Believe it or not, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed more than a year ago, and program changes begin in less than 6 months (January 1, 2017). MACRA will completely transform Medicare reimbursement and care delivery for oncology...
Former Clinical Director at the NCI, Gregory A. Curt, MD, Dies
In MemoriamGregory A. Curt, MD1952 – 2016 Gregory A. Curt, MD, Former Clinical Director at the National Cancer Institute (NCI) and nationally regarded expert on translational oncology died on July 31, 2016. He was 64 years old. Dr. Curt received his MD with distinction in research from the...
ASCO, Conquer Cancer Foundation Congratulate 2016 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.1 million in grants and awards to nearly 250 promising oncology researchers at the 2016 ASCO Annual Meeting. The Conquer Cancer Foundation and ASCO congratulate the recipients on their contributions to the field of oncology and...
Four Young Scientists Receive Damon Runyon–Sohn Pediatric Cancer Research Fellowship Awards
The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon–Sohn Pediatric Cancer Research Fellowship Award, committing nearly $1 million to help address a critical shortage of funding for pediatric cancer research. The...
My Oncologists Make Me Feel Safe Even While Living With Terminal Cancer
Looking back, I’m haunted by what might have been if my advanced non–small cell lung cancer (NSCLC) had been caught in its earliest stage, when perhaps a cure was possible. I certainly presented my physicians with enough clues—shortness of breath, coughing, and some body weakness—to have warranted...
Erratum
In the July 25 issue of The ASCO Post, the Letter to the Editor titled “Revisiting Ovarian Ablation in Early Breast Cancer: A Mismatch Between Global Values and Clinical Practice Guidelines,” by Richard R. Love, MD, appeared without a complete reference list. The ASCO Post apologizes to Dr. Love...
FDA Approves Extended-Release Granisetron Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) has approved an extended-release version of granisetron (Sustol) for the prevention of chemotherapy-induced nausea and vomiting, according to a news release by Heron Therapeutics, the drug’s manufacturer. Granisetron is an extended-release, injectable...
Clinical Trials Actively Recruiting Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on chronic lymphocytic leukemia. These studies are investigating multiple combination chemotherapies; regimens for relapsed and/or refractory disease; the role of inhibitors;...
Chamomile
Scientific Name: Matricaria recutita, Chamomilla recutita, Matricaria chamomilla Common Names: Hungarian chamomile, wild chamomile Overview An aromatic annual herb prevalent in Europe, North Africa, and Northwest Asia, chamomile has been used as a medicinal plant for several centuries. It has been ...
2016-2017 Oncology Meetings
AUGUST 16th World Congress on Cancers of the SkinAugust 31-September 3 • Vienna, AustriaFor more information: www.wccs2016.com 12th National Lymphedema Network International ConferenceAugust 31-September 4 • Dallas, TexasFor more information:https://cme.uchicago.edu/NLNIC16 SEPTEMBER ISOBM 2016...
Schwartz Center for Compassionate Healthcare Launches New Education and Training Programs
The Schwartz Center for Compassionate Healthcare recently announced the launch of two comprehensive educational offerings informed by the Compassionate, Collaborative Care—“The Triple C”—Framework, a new interdisciplinary model focused on improving quality and outcomes. The new educational...
Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer
As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...
FDA Approves Pembrolizumab for Metastatic Head and Neck Squamous Cell Carcinoma
On August 5, 2016, the U. S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or ...
A Complete Guide to Breast Surgery and Reconstruction
BookmarkTitle: Breast Cancer Surgery and Reconstruction: What’s Right for YouAuthor: Patricia Anstett, with photography by Kathleen GalliganPublisher: Rowman & LittlefieldPublication date: June 2, 2016Price: $35.00; hardcover, 224 pages Over the past 2 decades, we have seen tremendous...
Spotlight on ASCO’s Geriatric Oncology Webpage
With the increasing population of older adults with cancer, there has been a commensurate need for more readily available and widely accessible educational and clinical resources in geriatric oncology. As part of the Cancer and Aging Research Group and ASCO’s Geriatric Oncology Special Interest...
Surgical Oncologist Quan P. Ly, MD, FACS, Flees From Vietnam and Finds a Home at the University of Nebraska
After the Vietnam War, close to a million refugees, known as “boat people,” fled Vietnam, hazarding the open ocean on dangerously overloaded vessels. The term “boat people” is often used generically to refer to all the Vietnamese (about 2 million) who left their country by any means between 1975...
Six Perspectives on the Cancer Moonshot Goal of Making 10 Years of Progress in 5 Years
The Cancer Moonshot initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating 10 years of cancer research in 5 years. Achieving this outcome will...
Inotuzumab Ozogamicin Improves Outcomes vs Standard Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
In a phase III trial reported in The New England Journal of Medicine, Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that treatment with the antibody-drug conjugate inotuzumab ozogamicin resulted in a greater complete remission rate and improved ...
Prevalence of Estrogen Receptor Mutations in Patients With Metastatic Breast Cancer
A new study published online by JAMA Oncology examined the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.1 The activation of the estrogen receptor is a feature of most breast cancers in which estrogen receptor expression is detected. An...
Adding Bevacizumab to Letrozole Improves Progression-Free Survival but Increases Toxicity in Hormone Receptor–Positive Metastatic Breast Cancer
In a phase III trial (CALGB 40503/Alliance) reported in the Journal of Clinical Oncology, Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that the addition of bevacizumab (Avastin) to first-line endocrine therapy with letrozole improved progression-free...
Study Shows Women Who Received Cancer Screening Invitation Letters Are More Likely to Have a Pap Test
Receiving an invitation to undergo screening for cervical cancer is associated with a greater likelihood of getting screened, according to a study published by Tavasoli et al in Preventive Medicine.1 The study explored the impact of invitation and reminder letters on cervical cancer screening...
ESMO Releases New Consensus Guidelines on the Management of Metastatic Colorectal Cancer
The European Society for Medical Oncology (ESMO) has released new consensus guidelines for the management of metastatic colorectal cancer that reflect an increasingly personalized approach to treatment. These guidelines were published by Van Cutsem et al in Annals of Oncology.1 “Management of...
ASCO Endorses Cancer Care Ontario Recommendations on Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decisions in Early-Stage, Operable Breast Cancer
As reported in the Journal of Clinical Oncology (JCO) by N. Lynn Henry, MD, PhD, of University of Michigan Comprehensive Cancer Center, Ann Arbor, and colleagues,1 ASCO has endorsed Cancer Care Ontario guideline recommendations on the role of patient and disease factors in decisions on adjuvant...
Molly E. Collins, MD, Joins the Fox Chase–Temple University Hospital Pain and Palliative Care Program
Molly E. Collins, MD, has joined the Department of Hematology/Oncology at Fox Chase Cancer Center, providing additional physician support for the Fox Chase Cancer Center–Temple University Hospital Pain and Palliative Care Program. She assumed this position on August 1, 2016. “We’re very excited to ...
Indiana University School of Medicine Receives $2 Million Gift
The children of Indianapolis philanthropists Sidney and Lois Eskenazi have made a $2 million gift to the Indiana University School of Medicine to be used to recruit a highly accomplished researcher focused on discovering new ways to treat, diagnose, and prevent cancer. The gift, to honor their...
Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated
The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer. HRT is used to treat...
Increased Uveal Melanoma Risk Linked to Pigmentation Genes That Dictate Eye Color
New research links specific inherited genetic alterations to an increased risk for uveal melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. These findings were published by Ferguson et al in Scientific Reports. Previous clinical data suggests uveal melanoma...
ASTRO Awards $275,000 in Grants to Support Early Career Researchers in Radiation Oncology
The American Society for Radiation Oncology (ASTRO) has selected four early career scientists to receive a total of $275,000 in research awards, including one winner of the ASTRO Junior Faculty Career Research Training Award and three recipients of ASTRO Resident/Fellows in Radiation Oncology...
Ethan Basch, MD, MSc, Receives $5.45M Grant From PCORI to Study Patient-Reported Outcomes
The Patient-Centered Outcomes Research Institute (PCORI) has awarded Ethan Basch, MD, MSc, a 5-year, $5.45 million grant to support research into whether there are clinical benefits of having people with cancer self-report their symptoms while undergoing treatment. Dr. Basch, Director of the...
Understanding Double-Hit Lymphomas and Optimizing Management
Double-hit lymphomas are a challenging subset of high-grade B-cell lymphomas, previously characterized histologically as diffuse large B-cell lymphoma or B-cell lymphoma unclassifiable with intermediate features between diffuse large B-cell lymphoma and Burkitt lymphoma. Expert guidance in their...
ASCO’s 2016 Quality Training Program: Meet the First International Participant From Greece
Launched in 2014, ASCO’s Quality Training Program was developed to prepare oncology providers to design, implement, and lead successful quality-improvement activities in their practices. It is a 6-month program that includes a structured and facilitated improvement project selected by each...
GADOLIN and the Perplexing Role of Obinutuzumab in the Treatment of B-Cell Malignancies
After several dose-finding phase I and II studies in a variety of B-cell malignancies, the potential clinical role of the newer anti-CD20 monoclonal antibody obinutuzumab (Gazyva) remained unclear. These early trials tested low and high doses as well as weekly and every-3-week schedules of...
Phase III Trial Shows Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Laurie H. Sehn, MD, Chair, British Columbia Cancer Agency Lymphoma Tumor Group, and Clinical Associate Professor at the University of British Columbia, Vancouver, and colleagues, found that adding the anti-CD20 antibody obinutuzumab...
Late Cardiac Effects of Cancer Treatment
The combination of more precise diagnostic tools and advances in surgery, chemotherapy, radiation therapy, and targeted therapy in the treatment of cancer has led to unprecedented numbers of cancer survivors in the United States—more than 15.5 million, according to the latest figures from the...
AACR, Pancreatic Cancer Action Network Awards Research Grants to Early-Career Investigators
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network awarded nine grants to outstanding scientists who will undertake novel research in the field of pancreatic cancer. “By recruiting the brightest scientists with the most novel ideas, we continue to build a ...
Outcomes With Rituximab in DLBCL: Does Gender Matter?
For diffuse large B-cell lymphoma, does the dose of rituximab (Rituxan) matter? Are there patient characteristics that determine outcomes as well as the optimal dose? These questions were explored at the 2016 Pan Pacific Lymphoma Conference by Matthew A. Lunning, DO, Assistant Professor of...
AACR Holds Congressional Briefing to Reiterate Moonshot Goals and Plans
“We are in an era of unprecedented scientific opportunities in cancer research,” said Margaret Foti, PhD, MD (hc), Executive Officer, American Association for Cancer Research (AACR), as she introduced the Congressional briefing, “Seizing Today’s Opportunities to Accelerate Cancer Research.” “Thanks ...
New Preclinical Study Shows Esophageal Cancers Driven by 'Marginal Gain' Rather Than Speed
Wellcome Trust Sanger Institute scientists have shown that unexpectedly, esophageal cancer cells do not divide faster than their normal neighbors. Unlike normal cells, however, the tumor cells produce slightly more dividing daughter cells than nondividing cells, forming a tumor. The study,...
ASCO and SGO Release Clinical Practice Guideline on Neoadjuvant Therapy for Newly Diagnosed Advanced Ovarian Cancer
As reported by Alexi A. Wright, MD, MPH, of Dana-Farber Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO and the Society of Gynecologic Oncology (SGO) have released a clinical practice guideline on neoadjuvant therapy for patients with newly diagnosed stage IIIC or IV...
Combination Obinutuzumab Regimen Active in Aggressive Diffuse Large B-Cell Lymphoma
In a small phase Ib/II study, 100% of patients with newly diagnosed diffuse large B-cell lymphoma evaluated thus far responded to treatment with obinutuzumab (Gazyva), lenalidomide (Revlimid), and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), investigators from the University of...
Novel Approaches Harness the Microenvironment Against Hodgkin Lymphoma
In the treatment of classical Hodgkin lymphoma, antibodies targeting programmed cell death protein 1 (PD-1) are just the beginning, according to Stephen M. Ansell, MD, PhD, Professor of Medicine and Chair of the Lymphoma Group at the Mayo Clinic, Rochester, Minnesota.1 Speaking at the 2016 Pan...
What Is Scalp Cooling?
Scalp cooling is a means to lower scalp temperature to prevent hair loss during chemotherapy. Although there are several methods of scalp cooling, it often consists of a hypothermia cap connected to a computer-operating cooling and control unit. The system circulates coolant through channels in the ...
Scalp Cooling for Chemotherapy-Induced Alopecia Becoming Mainstream
Hair loss can be a devastating side effect of chemotherapy, but the recent U.S. Food and Drug Administration (FDA) approval of the DigniCap Cooling System and the growing acceptance of scalp-cooling methods in the United States may improve the quality of life for many patients receiving...
ASCO Guideline Addresses Controversial Areas in Adjuvant Therapy for Breast Cancer
ASCO has published an adaptation of the 2015 Cancer Care Ontario (CCO) clinical practice guideline on adjuvant chemotherapy for early-stage breast cancer.1 There were several areas of controversy that the guideline attempts to address. Should Anthracyclines Be Standard of Care? The guideline...
ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapies for HER2-Negative and HER2-Positive Breast Cancers
As reported in the Journal of Clinical Oncology by Neelima Denduluri, MD, and colleagues, ASCO has adapted a Cancer Care Ontario (CCO) clinical practice guideline on selection of optimal adjuvant chemotherapy for HER2-negative and adjuvant targeted therapy for HER2-positive breast cancer.1 The...
New Upfront Treatment Algorithm Emerges for Chronic Lymphocytic Leukemia
According to Susan M. O’Brien, MD, an expert in the treatment of chronic lymphocytic leukemia (CLL), novel agents and new data on patient subsets have led to a new upfront treatment algorithm for this malignancy. Speaking at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, Dr. O’Brien...
Have You Received Your Immune Checkpoint Inhibitor Yet?
“Have you received your immune checkpoint inhibitor yet?” I suspect St. Peter may have started asking this question routinely at the Pearly Gates to Heaven. If St. Peter has not, I am sure most oncologists have. With extensive media coverage on the approval of nivolumab (Opdivo) and pembrolizumab...
How the Oncology Center of Excellence Plans to Foster Collaboration Among Researchers to Advance Cancer Treatment
On June 29, 2016, Robert M. Califf, MD, MACC, the Commissioner of the U.S. Food and Drug Administration (FDA), announced the selection of Richard Pazdur, MD, FACP, as Acting Director of the FDA’s newly created Oncology Center of Excellence. The center was created in response to the overarching...
Racial/Ethnic Disparities in Genomic Sequencing
As scientists learn more about which genetic mutations are driving different types of cancer, they're targeting treatments to small numbers of patients, with the potential for big payoffs in improved outcomes. But even as we learn more about these driver mutations, a new study published by Spratt...
